These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31055599)

  • 1. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.
    Hyle EP; Scott JA; Sax PE; Millham LRI; Dugdale CM; Weinstein MC; Freedberg KA; Walensky RP
    Clin Infect Dis; 2020 Mar; 70(7):1353-1363. PubMed ID: 31055599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
    Koullias Y; Sax PE; Fields NF; Walensky RP; Hyle EP
    Clin Infect Dis; 2017 Oct; 65(8):1274-1281. PubMed ID: 28605418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
    Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G
    J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
    de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
    Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
    Hofstra LM; Sauvageot N; Albert J; Alexiev I; Garcia F; Struck D; Van de Vijver DAMC; Åsjö B; Beshkov D; Coughlan S; Descamps D; Griskevicius A; Hamouda O; Horban A; Van Kasteren M; Kolupajeva T; Kostrikis LG; Liitsola K; Linka M; Mor O; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stöckl E; Sönnerborg A; Staneková D; Stanojevic M; Van Laethem K; Zazzi M; Zidovec Lepej S; Boucher CAB; Schmit JC; Wensing AMJ; ; Puchhammer-Stockl E; Sarcletti M; Schmied B; Geit M; Balluch G; Vandamme AM; Vercauteren J; Derdelinckx I; Sasse A; Bogaert M; Ceunen H; De Roo A; De Wit S; Echahidi F; Fransen K; Goffard JC; Goubau P; Goudeseune E; Yombi JC; Lacor P; Liesnard C; Moutschen M; Pierard D; Rens R; Schrooten Y; Vaira D; Vandekerckhove LPR; Van den Heuvel A; Van Der Gucht B; Van Ranst M; Van Wijngaerden E; Vandercam B; Vekemans M; Verhofstede C; Clumeck N; Van Laethem K; Beshkov D; Alexiev I; Lepej SZ; Begovac J; Kostrikis L; Demetriades I; Kousiappa I; Demetriou V; Hezka J; Linka M; Maly M; Machala L; Nielsen C; Jørgensen LB; Gerstoft J; Mathiesen L; Pedersen C; Nielsen H; Laursen A; Kvinesdal B; Liitsola K; Ristola M; Suni J; Sutinen J; Descamps D; Assoumou L; Castor G; Grude M; Flandre P; Storto A; Hamouda O; Kücherer C; Berg T; Braun P; Poggensee G; Däumer M; Eberle J; Heiken H; Kaiser R; Knechten H; Korn K; Müller H; Neifer S; Schmidt B; Walter H; Gunsenheimer-Bartmeyer B; Harrer T; Paraskevis D; Hatzakis A; Zavitsanou A; Vassilakis A; Lazanas M; Chini M; Lioni A; Sakka V; Kourkounti S; Paparizos V; Antoniadou A; Papadopoulos A; Poulakou G; Katsarolis I; Protopapas K; Chryssos G; Drimis S; Gargalianos P; Xylomenos G; Lourida G; Psichogiou M; Daikos GL; Sipsas NV; Kontos A; Gamaletsou MN; Koratzanis G; Sambatakou H; Mariolis H; Skoutelis A; Papastamopoulos V; Georgiou O; Panagopoulos P; Maltezos E; Coughlan S; De Gascun C; Byrne C; Duffy M; Bergin C; Reidy D; Farrell G; Lambert J; O'Connor E; Rochford A; Low J; Coakely P; O'Dea S; Hall W; Mor O; Levi I; Chemtob D; Grossman Z; Zazzi M; de Luca A; Balotta C; Riva C; Mussini C; Caramma I; Capetti A; Colombo MC; Rossi C; Prati F; Tramuto F; Vitale F; Ciccozzi M; Angarano G; Rezza G; Kolupajeva T; Vasins O; Griskevicius A; Lipnickiene V; Schmit JC; Struck D; Sauvageot N; Hemmer R; Arendt V; Michaux C; Staub T; Sequin-Devaux C; Wensing AMJ; Boucher CAB; van de Vijver DAMC; van Kessel A; van Bentum PHM; Brinkman K; Connell BJ; van der Ende ME; Hoepelman IM; van Kasteren M; Kuipers M; Langebeek N; Richter C; Santegoets RMWJ; Schrijnders-Gudde L; Schuurman R; van de Ven BJM; Åsjö B; Kran AB; Ormaasen V; Aavitsland P; Horban A; Stanczak JJ; Stanczak GP; Firlag-Burkacka E; Wiercinska-Drapalo A; Jablonowska E; Maolepsza E; Leszczyszyn-Pynka M; Szata W; Camacho R; Palma C; Borges F; Paixão T; Duque V; Araújo F; Otelea D; Paraschiv S; Tudor AM; Cernat R; Chiriac C; Dumitrescu F; Prisecariu LJ; Stanojevic M; Jevtovic D; Salemovic D; Stanekova D; Habekova M; Chabadová Z; Drobkova T; Bukovinova P; Shunnar A; Truska P; Poljak M; Lunar M; Babic D; Tomazic J; Vidmar L; Vovko T; Karner P; Garcia F; Paredes R; Monge S; Moreno S; Del Amo J; Asensi V; Sirvent JL; de Mendoza C; Delgado R; Gutiérrez F; Berenguer J; Garcia-Bujalance S; Stella N; de Los Santos I; Blanco JR; Dalmau D; Rivero M; Segura F; Elías MJP; Alvarez M; Chueca N; Rodríguez-Martín C; Vidal C; Palomares JC; Viciana I; Viciana P; Cordoba J; Aguilera A; Domingo P; Galindo MJ; Miralles C; Del Pozo MA; Ribera E; Iribarren JA; Ruiz L; de la Torre J; Vidal F; Clotet B; Albert J; Heidarian A; Aperia-Peipke K; Axelsson M; Mild M; Karlsson A; Sönnerborg A; Thalme A; Navér L; Bratt G; Karlsson A; Blaxhult A; Gisslén M; Svennerholm B; Bergbrant I; Björkman P; Säll C; Mellgren Å; Lindholm A; Kuylenstierna N; Montelius R; Azimi F; Johansson B; Carlsson M; Johansson E; Ljungberg B; Ekvall H; Strand A; Mäkitalo S; Öberg S; Holmblad P; Höfer M; Holmberg H; Josefson P; Ryding U
    Clin Infect Dis; 2016 Mar; 62(5):655-663. PubMed ID: 26620652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
    Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.
    Zheng A; Kumarasamy N; Huang M; Paltiel AD; Mayer KH; Rewari BB; Walensky RP; Freedberg KA
    J Int AIDS Soc; 2018 Mar; 21(3):e25085. PubMed ID: 29603882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.
    Hauser A; Hofmann A; Meixenberger K; Altmann B; Hanke K; Bremer V; Bartmeyer B; Bannert N
    PLoS One; 2018; 13(11):e0206234. PubMed ID: 30408827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies.
    Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos R
    medRxiv; 2023 Apr; ():. PubMed ID: 37066200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic.
    Kleyn TJ; Liedtke MD; Harrison DL; Lockhart SM; Salvaggio MR; Ripley TL; Rathbun RC
    Ann Pharmacother; 2014 Apr; 48(4):470-5. PubMed ID: 24473489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.